Autoimmune Cytopenias

Given that autoimmune cytopenias (AICs) have been reported as a common complication in CLL with AIHA, the authors evaluated treatment of AICs in this setting. They conclude that, “because of their ability to mitigate an immunological dysregulation that is (at least partly) responsible for autoimmunity in CLL, to date BTK-inhibitors stand out as the most suitable choice when treatment of autoimmune cytopenias is required.”